Sutro Biopharma, Inc. (STRO)
9.33
-0.96
(-9.33%)
USD |
NASDAQ |
Oct 23, 16:00
9.335
0.00 (0.00%)
After-Hours: 20:00
Sutro Biopharma Enterprise Value : 240.16M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 240.16M |
| October 22, 2026 | 256.07M |
| October 21, 2026 | 264.36M |
| October 20, 2026 | 276.79M |
| October 19, 2026 | 272.07M |
| October 16, 2026 | 266.84M |
| October 15, 2026 | 275.46M |
| October 14, 2026 | 259.88M |
| October 13, 2026 | 268.00M |
| October 12, 2026 | 305.63M |
| October 09, 2026 | 322.04M |
| October 08, 2026 | 339.45M |
| October 07, 2026 | 328.51M |
| October 06, 2026 | 325.03M |
| October 05, 2026 | 336.30M |
| October 02, 2026 | 339.95M |
| October 01, 2026 | 350.22M |
| September 30, 2026 | 352.54M |
| September 29, 2026 | 352.38M |
| September 28, 2026 | 351.22M |
| September 25, 2026 | 350.39M |
| September 24, 2026 | 345.91M |
| September 23, 2026 | 346.24M |
| September 22, 2026 | 352.88M |
| September 21, 2026 | 356.52M |
| Date | Value |
|---|---|
| September 18, 2026 | 339.78M |
| September 17, 2026 | 342.10M |
| September 16, 2026 | 344.09M |
| September 15, 2026 | 360.00M |
| September 14, 2026 | 365.80M |
| September 11, 2026 | 364.98M |
| September 10, 2026 | 381.05M |
| September 09, 2026 | 389.76M |
| September 08, 2026 | 402.11M |
| September 04, 2026 | 418.19M |
| September 03, 2026 | 425.98M |
| September 02, 2026 | 424.82M |
| September 01, 2026 | 430.62M |
| August 31, 2026 | 421.00M |
| August 28, 2026 | 424.48M |
| August 27, 2026 | 438.74M |
| August 26, 2026 | 440.73M |
| August 25, 2026 | 440.89M |
| August 24, 2026 | 425.15M |
| August 21, 2026 | 434.26M |
| August 20, 2026 | 436.25M |
| August 19, 2026 | 448.69M |
| August 18, 2026 | 450.84M |
| August 17, 2026 | 454.82M |
| August 14, 2026 | 424.98M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Upstream Bio, Inc. | -110.28M |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -38.53M |
| Revenue (Quarterly) | 9.839M |
| Total Expenses (Quarterly) | 48.37M |
| EPS Diluted (Quarterly) | -2.325 |
| Gross Profit Margin (Quarterly) | 87.17% |
| Profit Margin (Quarterly) | -391.6% |
| Earnings Yield | -186.6% |
| Normalized Earnings Yield | -174.24 |